Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...
The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to ...
Originally approved in 2009, Stelara patents began expiring in 2023, leading to an influx of recent biosimilars.
Medpage Today on MSN9d
Alpha-Gal May Drive Sensitivity to IV Stelara in People With Red-Meat AllergiesORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in ...
Yesintek, formerly known as Bmab 1200, is a human interleukin-12 and -23 antagonist. The FDA has approved Yesintek (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab), for the treatment of ...
Bimekizumab – an IL-17A and IL-17F inhibitor – outdid both placebo and IL-12/IL-23 blocker Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic ...
Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...
SEOUL, South Korea, December 19, 2024--(BUSINESS WIRE)--Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback